drugset / Trial / NCT01147627
Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients
Completed
416 enrolled
Sun Yat-sen University
Amylin Pharmaceuticals, LLC. · collabEli Lilly and Company · collabMinistry of Health, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2 diabetic patients.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-08
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Exenatide | Peptide | 5 ug | — |
| Comparator | Exenatide | Peptide | 10 ug | — |
| Comparator | Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R | Protein / enzyme biologic | 0.4 iu/kg | — |
| Comparator | Pioglitazone | Small molecule | 45 mg | — |